Related Experiment Video
Updated: May 27, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
Published on: May 10, 2024
Clinical Management of Persistent Hypereosinophilia
Grzegorz Helbig1, Kacper Czachor1
1Department of Hematology and Bone Marrow Transplantation, Faculty of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
Abstract:
Blood eosinophilia remains a common finding in the general population, whereas hypereosinophilia (HE) is extremely rare. Different non-hematologic and hematologic disorders may be accompanied by blood eosinophilia. Clinical manifestations of eosinophilia-related disorders range from mild to life-threatening. Given the various symptoms, a comprehensive approach and close multidisciplinary cooperation are strongly recommended. Hypereosinophilic syndromes (HES) encompass a complex group of disorders defined as persistent peripheral blood HE ≥ 1500/mm3 and end-organ damage. An initial step in a diagnostic algorithm of HE includes the evaluation of secondary, potentially easy-to-treat causes. This HES variant is called reactive and often remains beyond the interest of hematologists. The further evaluation for primary causes of HE relies on a combination of different specialized tests, which are mostly available in hematologic centers and include most of all morphologic assessments of peripheral blood and bone marrow, cytogenetics, and molecular studies. Using these sophisticated methods, one can diagnose the specific HES subtypes based on genetic findings and categorize them according to currently applicable classifications. The choice of therapy differs between HES variants, ranging from corticosteroids and anti-interleukin-5 monoclonal antibodies for not-molecularly defined variants to oral molecules directed against molecular targets. This review presents eosinophilia-related disorders from a hematologic perspective.
Related Concept Videos
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
COPD: Management Using Bronchodilators and Corticosteroids
Cystic Fibrosis: Management
Sinus disease and chronic...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

